In Brief: Palomar
This article was originally published in The Gray Sheet
Executive Summary
Palomar: Management buy-out of firm's Albuquerque, New Mexico Tissue Technologies skin resurfacing laser subsidiary is announced Dec. 23. Palomar will retain a 15% equity stake in the business and receive warrants to buy an additional 10% stake and a "note receivable." Palomar also will receive royalties on all Tissue Technologies True-Pulse CO2 skin resurfacing lasers sold by the business. Palomar acquired the company, which is to be renamed Tissue Medical Lasers, in May 1996 in a stock swap transaction valued in the $20-30 mil. range ("The Gray Sheet" Feb. 19, 1996, I&W-5). The divestiture, which will help Palomar focus on its core laser-based hair removal business, follows the recent sale for $10 mil. of the firm's non-medical electronics subsidiaries to a management group led by officials of its Dynaco unit ("The Gray Sheet" Dec. 22, In Brief)...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.